Depression

 
HealthAshtam

Depression

DEPRESSION

Depression is a common but serious mental illness typically marked by sad or anxious feelings and manifests itself in the reduced efficiency.

Depression can describe a normal human emotion, it also can refer to a mental health illness.

It is defined as an illness when the feelings of depression persist and interfere with a child’s ability function.

TYPES OF DEPRESSION

CAUSES OF DEPRESSION

SYMPTOMS OF DEPRESSION

TYPES OF SYMPTOMS

THE EVOLUTION OF IMMUNITY

  • Products
  • FAQ
  • References
  • What does the liver do?

    The liver is the largest organ inside your body, and is essential to life, carrying out 500 different functions. It is the factory of the body, making proteins, blood clotting factors, and products to help with digestion and energy release. Your body uses it as a store for energy and iron. It also purifies the blood of bacteria, by-products of digestion, alcohol and drugs.

  • How can Liver health be affected?

    There are many causes of liver disease:-

    Drinking too much alcohol, usually over many years, is the single largest cause.

    There are also viruses that damage the liver; the most important are the blood-borne viruses hepatitis B and C.

    Some people lay down fat cells in their liver, often connected with being overweight or having diabetes.

    Other people carry genetic or develop autoimmune conditions that can lead to liver damage. It is also possible to suffer adverse reactions to medicines or drugs, resulting in liver failure.

    Cancer is both a cause and a consequence of liver disease. Finding the cause is important in designing the right treatment and stopping the progression of the disease.

  • My brother has been told he has cirrhosis. Does this mean he is an alcoholic?

    No, there are many different causes of cirrhosis. Alcohol is only one of these. Cirrhosis may be caused by viruses, iron overload, copper overload, metabolic disease, fat and autoimmune conditions.

  • What are the symptoms of liver disease?

    Liver disease is sometimes referred to as the 'silent killer' as there are often only vague symptoms until liver damage is quite severe. Early symptoms can include feeling generally unwell or tired, having poor appetite, weight loss, a tender abdomen, feeling itchy or vomiting. These are symptoms that are common in other medical conditions as well, however. Most people with liver disease only find out during tests for an unrelated illness or a medical check-up. When liver damage is quite severe, people can experience some of the following symptoms including yellow eyes and skin, called jaundice; bleeding problems; drowsiness and confusion; fever; swollen abdomen and legs; and tarry black stools or vomiting blood. If you have any of the symptoms consult your doctor.

  • How common is liver disease?

    Liver disease is on the increase and is now the fifth largest cause of deathin the UK. However, there are many more people living with liver disease and others who have a liver disease but are not aware of it. There are also a large number of people with a liver problem of some description, such as gallstones, and problems that resolve themselves over time without medical treatment. The British Liver Trust estimates that around 2 million people have a liver problem at any one time.

References

  • Abas M. Depression and anxiety among older Caribbean people in the UK: screening, unmet need and the provision of appropriate services. International Journal of Geriatric Psychiatry. 1996;11:377-382.
  • Abas MA, Phillips C, Carter J, et al. Culturally sensitive validation of screening questionnaires for depression in older African-Caribbean people living in south London. British Journal of Psychiatry. 1998;173:249-254.
  • Abbass A, Sheldon A, Gyra J, et al. Intensive short-term dynamic psychotherapy for DSM-IV personality disorders: a randomized controlled trial. Journal of Nervous and Mental Disease. 2008;196:211-216.
  • Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? European Archives of Psychiatry and Clinical Neuroscience. 2005;255:387-400.
  • AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care. 2003;12:18-23.
  • Ahn H, Wampold BE. Where oh where are the specific ingredients? A meta-analysis of component studies in counseling and psychotherapy. Journal of Counseling Psychology. 2001;48:251-257.
  • Akiskal HS. A developmental perspective on recurrent mood disorders: a review of studies in man. Psychopharmacology Bulletin. 1986;22:579-586.
  • Almond S, Healey A. Mental health and absence from work. Work, Employment and Society. 2003;17:731-742.
  • Altman D, Bland M. Statistics notes: Diagnostic tests 2: predictive values. British Medical Journal. 1994;309:102.
  • Altman D, Bland M. Statistics notes: Diagnostic tests 1: sensitivity and specificity. British Medical Journal. 1994;308:1552.
  • Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry. 2001;158:1617-1622.
  • American College of Sports Medicine. Guidelines for Graded Exercise Testing and Exercise Prescription. Madison, Wisconsin: American College of Sports Medicine; 1980.
  • Anderson IM, Edwards JG. Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness. Advances in Psychiatric Treatment. 2001;7:170-180.
  • Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2000;14:3-20.
  • Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2008;22:343-396.
  • Andrews G, Jenkins R, editors. Management of Mental Disorders (UK edn, vol. 1). Sydney: WHO Collaborating Centre for Mental Health and Substance Misuse; 1999.
  • Andrews G, Anderson TM, Slade T, et al. Classification of anxiety and depressive disorders: problems and solutions. Depression and Anxiety. 2008;25:274-281.
  • Anghelescu IG, Kohnen R, Szegedi A, et al. Comparison of hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomised multi-centre study. Pharmacopsychiatry. 2006;39:213-219.
  • Angst J. Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials: a meta-analysis of moclobemide trials. Human Psychopharmacology. 1993;8:401-407.
  • Angst J, Merikangas KR. Multi-dimensional criteria for the diagnosis of depression. Journal of Affective Disorders. 2001;62:7-15.
  • Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweizer Archiv fur Neurologie und Psychiatrie. 1995;146:5-16
  • Angst J, Merikangas KR. Multi-dimensional criteria for the diagnosis of depression. Journal of Affective Disorders. 2001;62:7-15.
  • Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweizer Archiv fur Neurologie und Psychiatrie. 1995;146:5-16
  • Angst J, Gamma A, Benazzi F, et al. Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidty and personality. Acta Psychiatrica Scandinavica. 2007;115(Suppl 433):72-84.
  • APA. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: APA; 1980. DSM-III.
  • APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA; 1994. DSM-IV.
  • APA. Handbook of Psychiatric Measures. Washington, DC: APA; 2000.
  • APA. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry. 2000;157(Suppl 4):1-45.
  • APA. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA; 2000. (4th edn Text Revision) (DSM-IV-TR)
  • Aragones E, Pinol JL, Labad A. The overdiagnosis of depression in non-depressed patients in primary care. Family Practice. 2006;23:363-368.
  • Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry. 1996;53:842- 848.
  • Arroll B, Goodyear-Smith F, Kerse N. Effect of the addition of a 'help' question to two screening questions on specificity for diagnosis of depression in general practice: diagnostic validation study. British Medical Journal. 2005;331:884-886.
  • Association of the British Pharmaceutical Industry. Edronax (reboxetine) SPC. Compendium of Data Sheets and Summaries of Product Characteristics. 2003. SPC available at:
  • Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Archives of General Psychiatry. 1976;33:1029-1037.
  • Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Progressive Neuro-psychopharmacology and Biology Psychiatry. 2004;28:57- 65.
  • Badamgarav E, Weingarten SR, Henning JM, et al. Effectiveness of disease management programs in depression: a systematic review. American Journal of Psychiatry. 2003;160:2080-2090.
  • Baer RA. Mindfulness training as a clinical intervention: a conceptual and empirical review. Clinical Psychology: Science and Practice. 2003;10:125-143.
  • Bailine SH, Rifkin A, Kayne E, et al. Comparison of bifrontal and bitemporal ECT for major depression. American Journal of Psychiatry. 2000;157:121-123
  • Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depression and Anxiety. 2005;22:68-76.
  • Baldwin DS, Cooper JA, Huusom AK, et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International Journal of Clinical Psychopharmacology. 2006;21:159-169.
  • Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental. 2009;24:269-275.
  • Ballard C, Bannister C, Solis M, et al. The prevalence, associations and symptoms of depression amongst dementia sufferers. Journal of Affective Disorders. 1996;36:135- 144.
  • Barber JP, Crits-Christoph P, Luborsky L. Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. Journal of Consulting and Clinical Psychology. 1996;64:619-622.
  • Barber JP, Gallop R, Crits-Christoph P, et al. The role of therapist adherence, therapist competence, and the alliance in predicting outcome of individual drug counseling: results from the NIDA Collaborative Cocaine Treatment Study. Psychotherapy Research. 2006;16:229-240.
  • Barbey JT, Roose SP. SSRI safety in overdose. Journal of Clinical Psychiatry. 1998;59(Suppl 15):42-48.
  • Barbosa L, Berk M, Vorster M. A double-blind, randomised, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry. 2003;64:403-407.
  • Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry. 2001;178:129-144.
  • Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal. 2009;180:291-297.
  • Barkow K, Heun R, Wittchen HU, et al. Mixed anxiety-depression in a 1 year follow-up study: shift to other diagnoses or remission? Journal of Affective Disorders. 2004;79:235-239.
  • Barrett JE, Williams JW, Oxman TE, et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. General Hospital Psychiatry. 1999;21:260-273.
  • Barrett JE, Williams JW Jr, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. Journal of Family Practice. 2001;50:405-412.
  • Bauer MS, Dunner DL. Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM-IV. Comprehensive Psychiatry. 1993;34:159-170.
  • Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. The World Journal of Biological Psychiatry. 2002;3:5-43
  • Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. The World Journal of Biological Psychiatry. 2002;3:69-86.
  • Beck AT. The past and future of cognitive therapy. Journal of Psychotherapy Practice and Research. 1997;6:276-284.
  • Beck AT. The evolution of the cognitive model of depression and its neurobiological correlates. American Journal of Psychiatry. 2008;165:969-977.
  • Beck AT, Beck JS. The Personality Belief Questionnaire. University of Pennsylvania; 1991.
  • Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561-571.
  • Beck AT, Rush AJ, Shaw BF, et al. Cognitive Therapy of Depression. New York: Wiley; 1979.
  • Beck AT, Steer A, Brown GK. Beck Depression Inventory Manual. 2nd ed. San Antonio, Texas: The Psychological Corporation; 1996.
  • Beck AT, Guth D, Steer RA, et al. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for primary care. Behaviour Research and Therapy. 1997;35:785-791.
  • Beck AT, Steer RA, Brown GK. BDI-Fast Screen for Medical Patients: Manual. San Antonio, Texas: The Psychological Corporation; 2000.
  • Beck JS. Cognitive Therapy: Basics and Beyond. New York: Guilford Press; 1995.
  • Beekman AFT, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life. British Journal of Psychiatry. 1999;174:307-311.
  • Benedicte A, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. Journal of Affective Disorders. 2010;120:94-104.
  • Benkert O, Szegedi A, Wetzel H, et al. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatrica Scandinavica. 1997;95:288-296.
  • Bennett KJ, Torrance GW, Boyle MH, et al. Cost-utility analysis in depression: the McSad utility measure for depression health states. Psychiatric Services. 2000;51:1171- 1176.
  • Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Journal of Affective Disorders. 2006;95:119-123.
  • Berlin JA. Does blinding of readers affect the results of metaanalyses? Lancet. 1997;350:185-186.
  • Bhugra D, Cochrane R. Psychiatry in a multi-ethnic context, Psychiatry in Multicultural Britain. Bhugra D, Cochrane R, editors. London: Gaskell; 2001.
  • Bhui K, Bhugra D, Goldberg D. Cross-cultural validity of the Amritsar Depression Inventory and the General Health Questionnaire amongst English and Punjabi primary care attenders. Social Psychiatry and Psychiatric Epidemiology. 2000;35:248-254.
  • Bhui K, Bhugra D, Goldberg D, et al. Cultural influences on the prevalence of common mental disorders, general practitioners� assessments and help-seeking among Punjabi and English people visiting their general practitioner. Psychological Medicine. 2001;31:815- 825.
  • Bhui K, Stansfeld S, Hull S, et al. Ethnic variations in pathways to and use of specialist mental health services in the UK. British Journal of Psychiatry. 2003;182:105-116.
  • Biddle L, Donovan JL, Gunnell D, et al. Young adults' perceptions of GPs as a help source for mental distress: a qualitative study. British Journal of General Practice. 2006;56:924-931.
  • Biddle S, Fox K, Edmund L. Physical Activity in Primary Care in England. London: Health Education Authority; 1994.
  • Black N. Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal. 1996;312:1215-1218.
  • Blackburn IM, Euson K, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. Journal of Affective Disorders. 1986;10:67-75.
  • Blashki TG, Mowbray R, Davies B. Controlled trial of amitriptyline in general practice. British Medical Journal. 1971;1:133-138.
  • Blom MB, Spinhoven P, Hoffman T, et al. Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. Journal of Affective Disorders. 2007;104:119-126.
  • Boeck V, Overo KF, Svendsen O. Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacologica et Toxicologica. 1982;50:169-174.
  • Bogetto F, Bellino S, Revello RB, et al. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs. 2002;16:273-283.
  • Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry. 1999;174:297-303.
  • Bordin ES. The generalizability of the psychoanalytic concept of the working alliance. Psychotherapy: Theory, Research and Practice. 1979;16:252-260.
  • Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. European Psychiatry. 2000;15:378-387.
  • Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. American Journal of Psychiatry. 2000;157:1925-1932.
  • Bower P, Gilbody S. Stepped care in psychological therapies: access, effectiveness and efficiency: narrative literature review. British Journal of Psychiatry. 2005;186:11-17.
  • Bower P, Sibbald B. On-site mental health workers in primary care: effects on professional practice, Cochrane Database of Systematic Reviews. 2000.
  • Bower P, Byford S, Sibbald B, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: Cost-effectiveness. British Medical Journal. 2000;321:1389-1392.
  • Bower P, Rowland N, Hardy R. The clinical effectiveness of counselling in primary care: a systematic review and meta-analysis. Psychological Medicine. 2003;33:203-215.